Dr. Esteva is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Lenox Hill Hospital
210 East 64th Street
New York, NY 10065Phone+1 212-434-4460
Summary
- I am interested in all aspects of breast cancer research and treatment. My research team discovered mechanisms of resistance to HER2 targeted therapy and he led clinical trials to overcome resistance in patients. I have co-authored over 200 publications, which encompass peer-reviewed research articles, invited reviews, and book chapters (H-index 84).
Education & Training
Georgetown University HospitalFellowship, Medical Oncology, 1994 - 1996
Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 1991 - 1994
Universidad de Zaragoza Faculty of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 2008 - Present
NY State Medical License 2013 - 2026
TX State Medical License 1998 - 2015
DC State Medical License 1994 - 2003
VA State Medical License 1996 - 2000- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
- Fellow (FACP) American College of Physicians, 2002
Clinical Trials
- Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer Start of enrollment: 2004 Dec 01
- Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer Start of enrollment: 2006 Apr 01
- The Impact of Obesity and Obesity Treatments on Breast Cancer Start of enrollment: 2009 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsTailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies.Francisco J Esteva, Elena Katz
JCO Oncology Practice. 2024-08-01 - 1 citationsLong-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic t...Xuexin He, Jiali Ji, Aiham Qdaisat, Francisco J Esteva, Sai-Ching J Yeung
Lancet Regional Health. Americas. 2024-04-01 - 4 citationsNext-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.Brittney S Zimmerman, Francisco J Esteva
Cancers. 2024-02-16
Journal Articles
- Expression of Human Endogenous Retrovirus-K Is Strongly Associated with the Basal-like Breast Cancer PhenotypeFrancisco J Esteva, Nature
Press Mentions
10 Recent Oncology PartnershipsAugust 23rd, 2024- Lenox Hill Hospital Names New Chief of Breast Medical OncologyJuly 25th, 2021
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019November 6th, 2019- Join now to see all
Grant Support
- Degradomic And Peptidomic Biomarkers For Early-Stage Breast CancerNational Center For Research Resources2011
- Fatty Acid Synthase And EGFR/HER2 Cross-Talk In Breast Cancer CellsNational Center For Research Resources2009–2011
- Liposomal BCL-2 Antisense Therapy For Solid TumorsNational Cancer Institute1999–2003
Professional Memberships
- Member
- Fellow
Other Languages
- Spanish
External Links
- Perlmutter Cancer Center at NYUhttp://cancer.med.nyu.edu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
